证券代码：002675 证券简称：东诚药业 公告编号：2023-048 烟台东诚药业集团股份有限公司 第五届监事会第十四次会议决议公告 本公司及监事会全体成员保证信息披露内容的真实、准确和完整，没有虚假记 载、误导性陈述或重大遗漏。 一、监事会会议召开情况 2023 年 8 月 31 日，烟台东诚药业集团股份有限公司（以下简称"公司"）第五 届监事会第十四次会议在山东省烟台经济技术开发区长白山路 7 号公司会议室召开。 会议通知于 2023 年 8 月 28 日以通讯方式发送至全体监事。本次会议由监事会主席 柳青林先生主持，应出席监事 3 人，实出席监事 3 人，董事会秘书刘晓杰先生列席， 符合法律法规及公司章程的有关规定。 二、监事会会议审议情况 （一）审议通过《关于下属公司实施期权激励计划暨关联交易的议案》 经审核，监事会认为：本次米度（烟台）生物技术有限公司（以下简称"烟台 米度"）实施期权激励计划，有利于健全公司及烟台米度的长效激励机制，充分调 动经营管理团队和核心骨干人员的积极性。本次交易遵循了自愿、公平合理、协商 一致的原则，审议程序符合法律、法规及《公司章程》的有关规定，不存在损害公 司及股东尤 ...

Financial Performance - The company reported a net profit of 18.10 million RMB for the current period, representing a 4.15% increase compared to the previous period[1]. - The company's revenue for the reporting period was approximately ¥1.79 billion, representing a year-on-year increase of 1.13% compared to ¥1.77 billion in the same period last year[53]. - The net profit attributable to the parent company was approximately CNY 1.36 billion, up from CNY 1.30 billion, representing a growth of about 4.5%[122]. - The net profit for the first half of 2023 was ¥223,066,187.90, compared to ¥202,354,461.04 in the previous year, indicating a growth of approximately 10.23%[168]. - The total comprehensive income for the first half of 2023 was CNY 221,150,702.56, compared to CNY 204,386,479.33, indicating a growth of approximately 8.2%[145]. Assets and Liabilities - The company has a total of 31.5 million RMB in assets related to its 70% stake in Zhongtai Biological Products Co., Ltd., located in Thailand[1]. - The total assets of Yantai Dongcheng Pharmaceutical Group reached approximately CNY 8.38 billion as of June 30, 2023, an increase from CNY 8.18 billion at the beginning of the year, reflecting a growth of about 2.5%[120]. - The company's total liabilities amounted to approximately CNY 2.95 billion, compared to CNY 2.89 billion at the start of the year, indicating an increase of around 2.1%[122]. - The total equity increased to ¥4,094,827,113.61 from ¥4,057,712,417.69, reflecting a growth of about 0.91%[168]. Cash Flow and Financing - The operating cash flow decreased significantly by 96.46% to ¥12.23 million, down from ¥345.07 million, primarily due to increased material payments[53]. - The company reported a net cash outflow from financing activities of approximately ¥109.79 million, a significant improvement of 228.12% compared to a net outflow of ¥85.69 million in the previous year[53]. - The net cash flow from financing activities was $36,830,350.73, a turnaround from a negative cash flow of $183,818,036.16 in the previous period, showcasing improved financial management[152]. - The total cash and cash equivalents at the end of the period amounted to $231,539,673.42, up from $158,338,408.76 in the previous period, representing a 46% increase[152]. Research and Development - The company's R&D investment surged by 117.96% to ¥162.94 million, up from ¥74.76 million, reflecting a strong commitment to innovation[53]. - The company established three major R&D platforms focusing on natural polysaccharide complex systems, Yiwensilan technology, and precision diagnosis and treatment of radiopharmaceuticals[47]. - The company is focusing on the development of innovative drugs targeting malignant tumors, neurodegenerative diseases, and cardiovascular conditions[47]. - Research and development expenses for the first half of 2023 were CNY 26,333,874.80, down from CNY 36,999,853.16, a decrease of about 29%[145]. Market and Product Development - The company completed the acquisition of 100% equity in XING IMAGING LLC for $30.2 million, aimed at enhancing its nuclear medicine clinical imaging capabilities[48]. - The company is focusing on the development of integrated radioactive diagnostic and therapeutic drugs, targeting various cancers[94]. - The company has launched two new positron emission tomography (PET) production centers, bringing the total to seven, with plans to exceed 30 centers by the end of 2023[69]. - The company is expanding its product line from heparin raw materials to low molecular weight heparin series products, including DCP118, to enhance market presence[100]. Regulatory and Compliance - The company is subject to increasingly stringent environmental regulations, which may raise costs related to pollution control and compliance[33]. - The company has obtained a new pollution discharge permit valid from December 14, 2022, to December 13, 2027, indicating compliance with environmental standards[40]. - The company received the "High-tech Enterprise Certificate" re-recognition, affirming its status as a high-tech enterprise[125]. - The financial statements confirm that there are no significant doubts regarding the company's ability to continue as a going concern for the next 12 months[194]. Shareholder Information - The largest shareholder, Dongyi Biotechnology Co., Ltd., holds 15.15% of the shares, totaling 124,888,049 shares[111]. - The total number of shares after the recent changes is 824,595,705, with 10.53% being restricted shares[126]. - The company distributed 123,689,355.75 CNY from profits to shareholders during the reporting period[183].

投资者关系活动 类别 □特定对象调研 □分析师会议 □媒体采访 ■业绩说明会 □新闻发布会 □路演活动 □现场参观 □其他 （ ） 参与单位名称及 人员姓名 通过"全景•路演天下"远程参与公司 2022 年度业绩网上说明会的广大 投资者。 时间 2023 年 5 月 9 日 15:00-17:00 地点 全景•路演天下（http://ir.p5w.net/） 上市公司接待人 员姓名 总经理：罗志刚 独立董事：赵大勇 董事会秘书：刘晓杰 财务总监：朱春萍 | | 99mTc 问题一： 标记替曲膦完成中检院的现场检查后，以过往经验，大概 | | --- | --- | | | 还需多久可以获批？目前这方面的销售推广有没提前开始？氟化钠注射 | | | 188Re]依替膦酸盐注射液有 液的进展是不是遇到问题，进度要推迟？铼[ | | | 可能实现有条件批准上市后再做三期临床吗？公司在这之前，仿创核药 | | | 的研发效率偏低是什么原因？有没有好的改革应对措施？ | | | 答：您好，公司各研发产品正按照公司预期计划推进，具体进展请您关 | | | 注相关定期报告。公司将依据研发产品的不同阶段的进展，及时履行信 | ...

Financial Performance - The company's revenue for Q1 2023 was CNY 850.50 million, a decrease of 3.32% compared to CNY 879.74 million in the same period last year[42]. - Net profit attributable to shareholders was CNY 50.11 million, down 8.77% from CNY 54.92 million year-on-year[42]. - The net cash flow from operating activities was CNY -92.82 million, a significant decline of 282.87% compared to CNY 50.76 million in the previous year[42]. - The net profit for the current period is ¥62,914,975.09, a decrease from ¥66,193,178.35 in the previous period, representing a decline of approximately 4.3%[62]. - The total comprehensive income for the current period is ¥60,401,256.33, down from ¥63,838,402.00 in the previous period, indicating a decrease of about 3.8%[62]. - The basic and diluted earnings per share for the current period are both ¥0.0608, compared to ¥0.0685 in the previous period, reflecting a decline of approximately 10.1%[63]. - The company reported a decrease in sales revenue from cash received for goods sold and services provided, totaling ¥836,066,401.59, down from ¥857,253,309.29 in the previous period[63]. Assets and Liabilities - The total assets at the end of the reporting period were CNY 8,264.59 million, an increase of 1.07% from CNY 8,176.85 million at the end of the previous year[42]. - The company's equity attributable to shareholders was CNY 4,792.97 million, reflecting a 0.93% increase from CNY 4,748.66 million year-on-year[42]. - The total current assets as of March 31, 2023, amounted to CNY 3,230,853,874.60, an increase from CNY 3,192,720,273.08 at the beginning of the year[58]. - The inventory balance increased to CNY 1,196,891,591.38 from CNY 1,078,053,484.87 at the beginning of the year[58]. - The total non-current assets were reported at CNY 2,257,000,000.00 as of March 31, 2023[58]. - The company reported a decrease in long-term equity investments to CNY 79,017,999.22 from CNY 86,616,680.24[58]. - The total liabilities as of March 31, 2023, were CNY 1,500,000,000.00, reflecting a stable financial position[58]. Cash Flow - Cash received from other operating activities increased by 134.53% year-on-year, mainly due to increased deposits received from market expansion in formulations[22]. - Cash received from investment decreased by 78.88% year-on-year, primarily due to a reduction in the maturity of wealth management products[23]. - Cash paid for investments decreased by 61.54% year-on-year, mainly due to a reduction in the purchase of wealth management products[24]. - The net cash flow from operating activities is negative at ¥92,824,560.09, a significant drop from a positive cash flow of ¥50,759,287.12 in the previous period[63]. - Cash inflow from operating activities totaled ¥909,740,103.97, while cash outflow was ¥1,002,564,664.06, resulting in a net cash outflow of ¥92,824,560.09[63]. - The net cash flow from investing activities is negative at ¥148,998,267.71, compared to a negative cash flow of ¥127,163,054.98 in the previous period[64]. - Cash inflow from financing activities is ¥128,300,000.00, while cash outflow is ¥23,562,226.66, leading to a net cash inflow of ¥104,737,773.34[64]. - The ending cash and cash equivalents balance is ¥785,354,287.20, an increase from ¥636,286,441.06 in the previous period[64]. - Cash and cash equivalents decreased to CNY 868,286,731.45 from CNY 1,021,623,576.58 at the beginning of the year[58]. Expenses - Sales expenses increased by 30.48% year-on-year, driven by increased market expenses in the formulation and nuclear medicine business[19]. - Financial expenses increased by 31.07% year-on-year, primarily due to exchange rate impacts resulting in foreign exchange losses[20]. - The company experienced a 90.24% decrease in cash paid for debt repayment, indicating reduced bank loan repayments[50]. - The company reported a 43.72% increase in management expenses, primarily due to costs associated with equity acquisitions[46]. - Other income increased by 299.55%, mainly due to an increase in government subsidies received[47]. Government Support and R&D - Government subsidies recognized in the current period totaled 9,589,346.86 RMB[5]. - The company’s subsidiary received approval for clinical trials of a new drug, indicating ongoing research and development efforts[28]. - The company received approval for a clinical trial of the drug 177 Lu-LNC1004, which will commence in Singapore[57]. Borrowings and Investments - Short-term borrowings increased by 33.70% compared to the beginning of the period, primarily due to increased bank loans[8]. - Trading financial assets increased by 151.92% compared to the beginning of the period, mainly due to the purchase of wealth management products[17].

Financial Performance - Yantai Dongcheng Pharmaceutical Group achieved a revenue of RMB 1.2 billion in 2022, representing a year-on-year growth of 15%[20] - The company reported a net profit of RMB 300 million for the year, an increase of 20% compared to the previous year[20] - The gross margin for 2022 was reported at 45%, with efforts to improve efficiency and reduce costs in the upcoming year[20] - The total revenue for the year 2022 was approximately 2,049,000,000 CNY, a decrease of 16.97% compared to 2021[69] - The main business cost for raw materials was 1,564,775,848 CNY, accounting for 76.54% of the total operating costs[69] - Total sales from the top five customers amounted to ¥1,064,964,438.98, accounting for 29.72% of the annual total sales[73] - Total purchases from the top five suppliers reached ¥788,801,331.34, which is 38.90% of the annual total purchases[73] - Research and development expenses increased by 18.87% to ¥163,520,492.52 compared to the previous year[77] - The number of R&D personnel rose by 69.83% to 394 in 2022, compared to 232 in 2021[81] - Total cash inflow from operating activities was ¥4,406,825,392.95, a 3.47% increase year-on-year[83] - Net cash flow from operating activities was ¥996,537,274.70, reflecting a 5.61% increase from the previous year[83] Market Expansion and Strategy - User data indicated a 25% increase in the number of active customers, reaching 500,000 by the end of 2022[20] - The company plans to expand its market presence in Southeast Asia, targeting a 30% market share by 2025[20] - The company has set a performance guidance of 10-15% revenue growth for 2023, driven by new product launches and market expansion strategies[20] - The company plans to continue expanding its market presence and investing in research and development to enhance its product offerings[120] Research and Development - The company has invested RMB 50 million in R&D for innovative drug delivery systems, aiming for completion by the end of 2023[20] - New product development includes a low molecular heparin product line, expected to launch in Q3 2023, projected to generate RMB 200 million in revenue[20] - The company is advancing multiple R&D projects aimed at enhancing its product pipeline, including new diagnostic and therapeutic nuclear drugs[78] Acquisitions and Partnerships - The company is exploring potential acquisitions in the biopharmaceutical sector to enhance its product portfolio and market reach[20] - The company has acquired a 70.28% stake in Nanjing Yunmi Enterprise Management Partnership for 35.2625 million RMB and a 99.90% stake in Nanjing Mi'anbei Enterprise Management Partnership for 114.5184 million RMB[50] - The company has purchased clinical approval and research data for the Tau protein PET imaging diagnostic drug for 8 million USD and 14 million RMB, gaining exclusive rights for clinical development, production, and market sales in mainland China[51] - The company has established partnerships with related parties, including the acquisition of shares in related partnerships[52] Financial Management - The company plans to raise a total of up to 349.997 million yuan through a non-public issuance of A shares, with all proceeds intended for replenishing working capital and repaying interest-bearing liabilities[88] - The company has confirmed that there are no overdue amounts in its entrusted financial management, with a total amount of 16,128 thousand yuan and an unexpired balance of 2,732.67 thousand yuan[85] - The company recognized a government subsidy of 200 million yuan, which contributed to an increase in cash flow from operating activities[116] - The company's cash and cash equivalents at year-end amounted to 1,021,623,577, representing 12.49% of total assets, up from 10.80% at the beginning of the year[118] Compliance and Quality Assurance - The company is committed to maintaining compliance with GMP standards across all manufacturing processes to ensure product quality and safety[20] - The company's heparin sodium raw materials passed the official audit by the Korean Ministry of Food and Drug Safety, receiving an audit confirmation letter[91] - The company's technology center has been recognized as a national enterprise technology center in the 29th batch of new recognitions by the National Development and Reform Commission and other authorities[91] Shareholder Information - The company issued 22,381,379 shares on October 20, 2022, increasing total shares from 802,214,326 to 824,595,705[133] - The largest shareholder, Yantai Dongyi Biological Engineering Co., Ltd., holds 15.15% of the shares, totaling 124,888,049 shares[138] - The actual controller of the company is You Shiyi, who holds 51% of Yantai Dongyi Biological Engineering Co., Ltd.[142] Government Subsidies - The company’s subsidiary Dongcheng Nuclear Medicine received a government subsidy of RMB 100 million from the Yantai Municipal Government on April 8, 2022, to support the integration of the nuclear medicine industry[94] - Dongcheng Nuclear Medicine received an additional government subsidy of RMB 90 million on July 19, 2022, from the Yantai Municipal Government[94] - On December 15, 2022, Dongcheng Nuclear Medicine received a further government subsidy of RMB 10 million from the Yantai Municipal Government[94]

为充分尊重投资者、提升交流的针对性，现就公司 2022 年度网上业绩说明 会提前向投资者公开征集问题，广泛听取投资者的意见和建议。投资者可于 2023 年 5 月 8 日（星期一）17：00 前访问 http://ir.p5w.net/zj/，或扫描下方二维码，进 入问题征集专题页面。公司将在 2022 年度网上业绩说明会上，对投资者普遍关 注的问题进行回答。 欢迎广大投资者积极参与。 （问题征集专题页面二维码） 证券代码：002675 证券简称：东诚药业 公告编号：2023-024 烟台东诚药业集团股份有限公司 关于举行 2022 年度报告网上业绩说明会的公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有 虚假记载、误导性陈述或重大遗漏。 烟台东诚药业集团股份有限公司（以下简称"公司"）定于 2023 年 5 月 9 日 （星期四）15：00—17:00 举行 2022 年度网上业绩说明会。本次业绩说明会将 采用网络远程的方式举行，投资者可登陆投资者关系互动平台（网址： http://ir.p5w.net/）参与本次业绩说明会。 出席本次年度业绩说明会的人员有：公司总经理罗志刚先生、财务负 ...

证券代码：002675 证券简称：东诚药业 烟台东诚药业集团股份有限公司投资者关系活动记录表 编号：2015-001 | --- | --- | --- | --- | |----------------|---------------------------------|--------------------------------------------------------|-------| | | | | | | 投资者关系活动 | | ■特定对象调研 □分析师会议 | | | 类别 | | □媒体采访 □业绩说明会 | | | | □新闻发布会 □路演活动 | | | | | □现场参观 | | | | | | □其他 （请文字说明其他活动内容） | | | 参与单位名称及 | 华创证券 张文录 | | | | 人员姓名 | 中信建投证券 高君 | | | | | 国都证券 姚巍 | | | | | 上投摩根基金 方钰涵 | | | | | 交银施罗德基金 张胤 | | | | | 交银施罗德基金 芮晨 | | | | | 博时基金 蔡滨 | | | | | 博时基金 葛晨 | | | | | ...

证券代码：002675 证券简称：东诚药业 烟台东诚药业集团股份有限公司投资者关系活动记录表 烟台东诚药业集团股份有限公司投资者关系活动记录表 股份有限公司投资者关系活动记录表 编号：2015-002 | --- | --- | --- | --- | --- | |-----------------------------|----------------------------------|--------------------------------------------------------|-------|-------| | | | | | | | 投资者关系活动 | | ■特定对象调研 □分析师会议 | | | | 类别 | | □媒体采访 □业绩说明会 | | | | | □新闻发布会 □路演活动 | | | | | | □现场参观 | | | | | | □其他 （请文字说明其他活动内容） | | | | | 参与单位名称及 | 平安证券 叶寅 | | | | | 人员姓名 | 招商证券 李勇剑 | | | | | | 财通证券 顾明豪 | | | | | | 东兴证券 贾丽杰 | | ...